Arcus Biosciences, Inc. (NYSE:RCUS) Receives $33.33 Consensus PT from Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $33.8889.

Several research analysts have recently issued reports on the stock. Wedbush boosted their price objective on shares of Arcus Biosciences from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Morgan Stanley boosted their price objective on shares of Arcus Biosciences from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Monday, May 11th. Wells Fargo & Company set a $23.00 price objective on shares of Arcus Biosciences and gave the stock an “equal weight” rating in a report on Thursday, February 12th. Leerink Partners set a $47.00 price objective on shares of Arcus Biosciences in a report on Monday, April 20th. Finally, Citigroup boosted their price objective on shares of Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, March 5th.

Arcus Biosciences Stock Performance

Shares of RCUS opened at $23.77 on Thursday. The company has a market capitalization of $2.99 billion, a PE ratio of -7.47 and a beta of 0.87. Arcus Biosciences has a one year low of $7.91 and a one year high of $28.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The company’s fifty day moving average price is $23.38 and its 200 day moving average price is $22.48.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The firm had revenue of $17.00 million during the quarter, compared to the consensus estimate of $29.49 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The business’s revenue was down 39.3% compared to the same quarter last year. During the same quarter last year, the business earned ($1.14) EPS. As a group, analysts expect that Arcus Biosciences will post -3.54 earnings per share for the current year.

Insider Activity

In other news, CFO Robert C. Goeltz II sold 7,763 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $25.63, for a total transaction of $198,965.69. Following the transaction, the chief financial officer owned 84,161 shares in the company, valued at approximately $2,157,046.43. The trade was a 8.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.60% of the company’s stock.

Institutional Trading of Arcus Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RCUS. Hantz Financial Services Inc. increased its stake in Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after acquiring an additional 881 shares during the period. SBI Securities Co. Ltd. increased its stake in Arcus Biosciences by 13,547.6% in the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after acquiring an additional 2,845 shares during the period. T. Rowe Price Investment Management Inc. bought a new stake in Arcus Biosciences in the fourth quarter valued at about $39,000. KBC Group NV bought a new stake in Arcus Biosciences in the first quarter valued at about $50,000. Finally, Strs Ohio bought a new stake in Arcus Biosciences in the first quarter valued at about $67,000. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.